Laura Wood on Multidisciplinary Collaboration for Managing Immunotherapy Adverse Events
Laura Wood on collaboration between departments when treating patients with cancer who are receiving immunotherapy treatments.
Laura Wood, RN, MSN, OCN, Cleveland Clinic explains the importance of a multidisciplinary approach when treating patients on immunotherapy.
Patients receiving immunotherapy treatments have autoimmune-type adverse events that are unlike those of chemotherapy. The side effects can be prolonged and require careful monitoring as well as multidisciplinary collaboration. Checking in with gastrointestinal, endocrinology, and other specialists can help to manage and monitor these side effects.
Nurses Compare Tactics in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
December 18th 2023During a Case-Based Roundtable™ event, Beth Faiman, Phd, CNP, and participants discussed the use of combination therapies, including daratumumab, as frontline therapy for patients with transplant-ineligible multiple myeloma.
Approaches to Urothelial Carcinoma Care Call for Nuanced AE Management
August 11th 2022Avelumab, erdafitinib, and enfortumab vedotin-ejfv are 3 critical drugs in the treatment of urothelial cancer with distinct safety profiles, according to a presentation at the 6th Annual School of Nursing Oncology™ Meeting.
